Amoxicillin-Clavulanic Acid Resistance in the Genus Bifidobacterium
- 11 March 2021
- journal article
- research article
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 87 (7)
Abstract
Amoxicillin-Clavulanic acid (AMC) is one of the most frequently prescribed antibiotic formulations in the Western world. Extensive oral use of this antimicrobial combination influences the gut microbiota. One of the most abundant early colonizers of the human gut microbiota is represented by different taxa of the Bifidobacterium genus, which include many members that are considered to bestow beneficial effects upon their host. In the current study, we investigated the impact of AMC administration on the gut microbiota composition, comparing the gut microbiota of 23 children that had undergone AMC antibiotic therapy to that of 19 children that had not been treated with antibiotics during the preceding six months. Moreover, we evaluated AMC sensitivity by Minimal Inhibitory Concentration (MIC) test of 261 bifidobacterial strains, including reference strains for the currently recognized 64 bifidobacterial (sub)species, as well as 197 bifidobacterial isolates of human origin. These assessments allowed the identification of four bifidobacterial strains, which exhibit a high level of AMC insensitivity, and which were subjected to genomic and transcriptomic analyses to identify the putative genetic determinants responsible for this AMC insensitivity. Furthermore, we investigated the ecological role of AMC-resistant bifidobacterial strains by in vitro batch-cultures. Importance Based on our results, we observed a drastic reduction in gut microbiota diversity of children treated with antibiotics, also affecting the abundance of Bifidobacterium, a bacterial genus commonly found in the infant gut. MIC experiments revealed that more than 98% of bifidobacterial strains tested were shown to be inhibited by the AMC antibiotic. Isolation of four insensitive strains and sequencing of their genome revealed the identity of possible genes involved in AMC resistance mechanisms. Moreover, gut-simulating in-vitro experiments revealed that one strain, i.e. B. breve PRL2020, is able to persist in the presence of a complex microbiota combined with AMC antibiotic.Keywords
Funding Information
- Science Foundation Ireland (SFI/12/RC/2273-P1)
- Science Foundation Ireland (SFI/12/RC/2273-P2)
This publication has 61 references indexed in Scilit:
- High-Throughput Sequencing Reveals the Incomplete, Short-Term Recovery of Infant Gut Microbiota following Parenteral Antibiotic Treatment with Ampicillin and GentamicinAntimicrobial Agents and Chemotherapy, 2012
- Identification of acquired antimicrobial resistance genesJournal of Antimicrobial Chemotherapy, 2012
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell SequencingJournal of Computational Biology, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental dataBioinformatics, 2011
- PGAP: pan-genomes analysis pipelineBioinformatics, 2011
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- Prodigal: prokaryotic gene recognition and translation initiation site identificationBMC Bioinformatics, 2010
- Updated Functional Classification of β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- UniFrac: a New Phylogenetic Method for Comparing Microbial CommunitiesApplied and Environmental Microbiology, 2005